Peanut (Ara h 1) IgE

If you or your child has had an unclear reaction after eating peanut, a standard peanut allergy test often leaves more questions than answers. Sensitization shows up easily on basic skin prick tests and whole-peanut blood tests, but many sensitized people can eat peanut without problems. This test zooms in on one specific peanut protein, Ara h 1 (a major peanut storage protein), to help separate true allergy from background sensitization.

Ara h 1 IgE (immunoglobulin E, the antibody class that drives allergic reactions) is part of a panel of peanut component tests. On its own it is a supporting marker, not a final answer. Read alongside Ara h 2 and a careful history, it helps clarify how your immune system actually sees peanut and what that might mean for your risk of a reaction.

What This Test Actually Measures

Peanut contains many proteins, but only a few drive real allergic reactions. Ara h 1 is a 7S vicilin-family seed storage protein. It is one of three peanut seed storage proteins tied to genuine peanut allergy, alongside Ara h 2 (a 2S albumin) and Ara h 3 (an 11S legumin), each from a different structural family. The test measures IgE antibodies in your blood that specifically recognize Ara h 1. These antibodies are produced by your immune cells, with peanut allergy research showing a reservoir of IgE-producing cells lining the stomach and upper small intestine.

When peanut protein contacts these antibodies later, the antibodies signal mast cells and basophils (allergy-trigger cells) to release histamine and other chemicals, producing the symptoms of a peanut reaction. A higher Ara h 1 IgE level means your immune system has built up a stronger antibody response against this stable, heat-resistant peanut protein.

Peanut Allergy Diagnosis

Peanut allergy is one of the most common and persistent food allergies. The hard part is not detecting peanut sensitization but separating true reactors from people who carry peanut antibodies but tolerate peanut fine. Component testing of Ara h 1, 2, and 3 was developed specifically to close that gap.

In Japanese children with confirmed peanut allergy, having positive IgE to all three storage proteins (Ara h 1, 2, and 3) together raised specificity to 94%, meaning very few tolerant children were wrongly flagged. In US infants screened before peanut introduction, a study found Ara h 1 and Ara h 3 IgE added no extra predictive value once Ara h 2 IgE was known. A pooled meta-analysis estimated Ara h 1 IgE sensitivity at about 37% at the standard 0.35 kU/L cutoff. A Turkish multiplex study confirmed that IgE to Ara h 1, 2, 3, and 6 together predicts real clinical reactivity, but again as a panel rather than Ara h 1 alone.

What this means for you: Ara h 1 IgE is most useful as part of a component panel. A positive result, especially with positive Ara h 2 and Ara h 3, makes true peanut allergy more likely. A negative Ara h 1 with a positive Ara h 2 still points to allergy. Decisions about whether to eat peanut, do an oral food challenge, or start treatment depend on the full picture, not Ara h 1 alone.

Sensitization Patterns and Cross-Reactivity

Ara h 1 IgE also helps map how your immune system sees peanut. In a large US laboratory dataset, many children showed sensitization to storage proteins Ara h 1, 2, or 3, and some were Ara h 1 or 3 positive without Ara h 2, suggesting Ara h 1 catches additional sensitized people. In Polish children, Ara h 1 was a common sensitization target on multiplex testing, found in about 16 of every 100 tested.

In Southern Chinese adults with allergic rhinitis or asthma, about 21 of every 100 peanut-sensitized people had Ara h 1 IgE, often alongside pollen sensitization. This pattern can reflect cross-reactivity, where antibodies trained against one protein recognize a related one. Knowing the dominant component changes how seriously to interpret the result, because storage protein sensitization carries more reaction risk than pollen-driven cross-sensitization.

Tracking Response to Oral Immunotherapy

If you or your child is undergoing peanut oral immunotherapy, the goal is to retrain the immune system to tolerate peanut. Ara h 1 IgE is one window into whether that retraining is happening. In a Finnish cohort doing peanut oral immunotherapy, Ara h 1 IgE often stayed steady while IgG4 (a blocking antibody) against Ara h 1 rose markedly over 8 to 19 months. In a long-term study with a median 41 months of treatment, total peanut IgE dropped substantially, with falls across Ara h 1, 2, and 3.

An epicutaneous immunotherapy trial (a daily patch worn on the skin) found that Ara h 1 IgE rose at month 3 then fell below baseline by month 12, and an Ara h 1 IgE below 15.7 kU/L at month 12 was the best component-level predictor of successful desensitization. In the same analysis, the peanut IgG4 to IgE ratio was the strongest single predictor overall. The number itself is less important than the trajectory.

Why One Reading Is Not Enough

A single Ara h 1 IgE value gives you a snapshot, but allergy biology changes over months and years. In a population-based cohort followed from age 1 to age 10, peanut and Ara h 2 IgE generally decreased in children whose allergy resolved and stayed higher in those whose allergy persisted. About one in three infants with peanut allergy outgrew it by age 10. Tracking your trend reveals whether you are heading toward resolution, toward persistence, or toward successful desensitization with therapy.

A practical cadence, based on expert clinical practice rather than a formal guideline: get a baseline, retest in 6 to 12 months if you are managing peanut allergy or doing immunotherapy, and at least annually thereafter. For children whose allergy may be resolving, retesting yearly is reasonable until levels fall enough to consider a supervised oral food challenge. Compare your trajectory against the same component over time, not against a number from a different lab or method.

When Results Can Be Misleading

A few situations can make a single Ara h 1 IgE reading harder to interpret correctly. Most are about context, not lab error.

• Sensitization without allergy: many people have detectable Ara h 1 IgE but tolerate peanut without symptoms. A positive result alone does not prove clinical allergy without history and supporting tests.
• Pollen cross-reactivity: in pollen-sensitized people, antibodies built against pollen proteins can recognize related peanut proteins, producing a positive result without true peanut allergy risk.
• Assay platform differences: different commercial IgE platforms can give different numerical values for the same sample. Compare results from the same method, not across platforms.
• Very low levels with real allergy: in some cases, especially with negative skin prick test, real peanut allergy can exist with very low or undetectable component IgE. A negative Ara h 1 IgE does not fully rule out allergy if history is strongly suggestive.

What to Do With an Unexpected Result

If your Ara h 1 IgE comes back positive, the next step is to look at the rest of the component panel, especially Ara h 2 and Ara h 6, and to put the result alongside your history. A positive Ara h 1 with a positive Ara h 2 and a clinical history of reaction is strong evidence of true allergy and a reason to keep strict avoidance and emergency epinephrine on hand. A positive Ara h 1 with a negative Ara h 2 and no symptoms after peanut exposure warrants a conversation with an allergist about whether an oral food challenge or a basophil activation test would clarify the picture.

If your results are confusing or contradict your symptoms, an allergist can integrate component testing with functional assays (such as the basophil activation test) to resolve the picture. If you are doing oral immunotherapy, declining Ara h 1, 2, and 3 IgE alongside rising IgG4 ratios is a favorable pattern. If levels are not budging despite consistent therapy, your provider may want to review the protocol or look at additional immune markers.